Stocks

When asked by a Twitter user if he showed any symptoms, Musk said he had symptoms of a "typical cold."

Data-analytics company cites pandemic-related government contracts

Instacart was valued at $17.7 billion last month, when it raised $200 million in a private fundraising round

Cisco Systems Inc reported a smaller-than-expected drop in first-quarter revenue as more people working from home during the COVID-19 pandemic drove demand for its teleconferencing tools, networking equipment and cybersecurity products.

Disney was already making heavy investments in Disney+ and sister service ESPN+ prior to pandemic, which has triggered a surge in digital viewership.

President Trump is taking new actions against China.

Southwest Airlines Co. says a pickup in bookings over the past three months is slowing as a second wave of COVID-19 infections sweeps across the country.

A coronavirus vaccine would restore economic growth and break up the stock market's yearlong love affair with Big Tech, according to strategists at Goldman Sachs Group.

Small cap stocks are staging a comeback. Here's why...

Investors are toggling between growth and cyclical plays this week.

For the holidays, FedEx is hiring 70,000 workers, while UPS is in the throes of hiring more than 100,000 temporary employees

A U.S.-China agreement allows both countries to operate more than 100 weekly flights between the two nations

Traders will dissect the latest data on jobless claims and consumer prices

Foxconn booked July-September net profit of T$30.8 billion ($1.08 billion)

Sony has made launch sales online only to maintain social distancing

Chinese airlines will need 8,600 new airplanes through 2039, 6.3% higher than Boeing's previous prediction

Kodak Finance Chief David Bullwinkle said on an earnings call Tuesday that the company had discovered deficiencies in its controls that had failed to prevent the “unauthorized issuance” of the company’s stock.

Pfizer and German partner BioNTech announced on Monday that their COVID-19 vaccine candidate, which was developed in record time, was found to have a 90% positive efficacy rate and could start being distributed before the end of the year.

Albert Bourla sold 132,508 Pfizer shares at a price of $41.94 apiece through a scheduled Rule 10b5-1 trading plan adopted on Aug. 19, one day after the company announced positive results from a Phase 1 study.

Investors dipped backed into growth stocks Wednesday.